Pharmaron's equity-participating company, Yaojie Ankang, has successfully debuted on the main board of the Hong Kong Stock Exchange. Pharmaron maintains an ownership stake of approximately 5.78% in Yaojie Ankang. These shares are accounted for as financial assets, measured at fair value through other comprehensive income, and classified under investments in other equity instruments. Following the listing, Pharmaron's accounting treatment of these shares will remain consistent, with the actual financial implications to be determined by the subsequent audit report.